Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Bluebird scores second gene therapy approval

by Shi En Kim
September 25, 2022 | A version of this story appeared in Volume 100, Issue 34

 

Bluebird Bio has received approval from the US Food and Drug Administration for the gene therapy elivaldogene autotemcel, branded as Skysona. The treatment slows the progression of neurologic dysfunction in young boys with cerebral adrenoleukodystrophy. The go-ahead comes within a month of an FDA approval for Bluebird’s other gene therapy, Zynteglo, which treats the blood disorder β-thalassemia. Priced at $3 million for a full treatment, Skysona has eclipsed Zynteglo as the world’s most expensive drug.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.